Aurinia Pharmaceuticals Inc Monday presented highlights from its phase IIb AURA study of voclosporin for the treatment of lupus nephritis saying the drug met its primary endpoint and all secondary endpoints. The data was presented at the American Society of Nephrology Kidney Week 2016 on November 19, 2016.
“There is a critical unmet need for an effective therapeutic treatment of LN, a devastating and life-altering disease that, if left untreated, can lead to end-stage renal disease and even death,” said principal investigator Dr. William Pendergraft. “Until now, the LN clinical trial landscape has been bleak, but AURA is now the first global study in active LN to meet its primary endpoint and all pre-specified secondary endpoints.”
The AURA study remains ongoing until its 48-week secondary endpoints, which will be completed in Q1 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.